Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.59 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.58 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.55 |
| ▸ | LDHA | P00338 | 1/20 | 0.55 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.52 |
| ▸ | CA1 | P00915 | 1/20 | 0.47 |
| ▸ | CA2 | P00918 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | AGXT | P21549 | 1/20 | 0.47 |
| ▸ | PPARG | P37231 | 1/20 | 0.46 |
| ▸ | PPARA | Q07869 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL1403833 | 0.98 | POLB (0.58) | POLBSLC6A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL5859651 | 0.88 | LDHA (0.62) | POLBSLC6A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL1815225 | 0.82 | POLB (0.57) | POLBSLC6A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL2481968 | 0.82 | POLB (0.57) | POLBSLC6A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL1551932 | 0.81 | POLB (0.55) | POLBSLC6A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL28222288 | 0.81 | PPARG (0.63) | POLBSLC6A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL1551930 | 0.81 | POLB (0.55) | POLBSLC6A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL10678215 | 0.80 | SLC6A4 (0.68) | POLBSLC6A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL2334749 | 0.79 | SLC6A4 (0.67) | POLBSLC6A4CYP2D6CYP1A2CYP2C19 | |
| SCHEMBL14402484 | 0.79 | POLB (0.54) | POLBSLC6A4CYP2D6CYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2009135526-A1 | ALPHA-MERCAPTO-AMIDES | NOVARTIS AG (CH) | 2009-11-12 | — | — | WO | disclosed |
| US-7429594-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429594-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-09-30 | — | — | US | disclosed |
| US-7429594-B2 | Substituted heterocyclic compounds and methods of use | AMGEN INC. (US) | 2008-09-30 | — | — | US | disclosed |
| EP-1656366-A1 | SUBSTITUTED PYRIMDINONE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2006-05-17 | — | — | EP | disclosed |
| WO-2005019202-A1 | SUBSTITUTED PYRIMDINONE DERIVATIVES AND METHODS OF USE | AMGEN INC. (US) | 2005-03-03 | — | — | WO | disclosed |
| US-20050043301-A1 | Substituted heterocyclic compounds and methods of use | AMGEN INC. | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043301-A1 | Substituted heterocyclic compounds and methods of use | MYLK2, MYLK, MCL1 | POLB 2945/4885SLC6A4 4575/4885CYP2D6 1800/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.